Protagenic Therapeutics (PTIX) Insider Trading & Ownership $0.56 +0.04 (+7.69%) (As of 12/17/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrends Protagenic Therapeutics (NASDAQ:PTIX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage37.00%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$22,810.00Number OfInsiders Selling(Last 3 Years)0 Get PTIX Insider Trade Alerts Want to know when executives and insiders are buying or selling Protagenic Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address PTIX Insider Buying and Selling by Quarter Ad Crypto 101 MediaAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDiscover our #1 crypto pick before it's too late. Protagenic Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/12/2023Alexander K ArrowCFOBuy8,000$0.81$6,480.00 5/17/2022Alexander K ArrowCFOBuy23,000$0.71$16,330.00 (Data available from 1/1/2013 forward) PTIX Insider Trading Activity - Frequently Asked Questions Who is on Protagenic Therapeutics's Insider Roster? The list of insiders at Protagenic Therapeutics includes Alexander K Arrow. Learn more on insiders at PTIX. What percentage of Protagenic Therapeutics stock is owned by insiders? 37.00% of Protagenic Therapeutics stock is owned by insiders. Learn more on PTIX's insider holdings. Which Protagenic Therapeutics insiders have been buying company stock? The following insider purchased PTIX shares in the last 24 months: Alexander K Arrow ($6,480.00). How much insider buying is happening at Protagenic Therapeutics? Insiders have purchased a total of 8,000 PTIX shares in the last 24 months for a total of $6,480.00 bought. Protagenic Therapeutics Key ExecutivesDr. Garo H. Armen Ph.D. (Age 71)Co-Founder & Executive Chairman of the Board Dr. Alexander Kenneth Arrow C.F.A. (Age 53)M.D., CFO & Secretary Compensation: $150kDr. Andrew Slee Ph.D. (Age 74)Chief Operating Officer Dr. Robert Benjamin Stein M.D. (Age 73)Ph.D., Chief Medical Officer & Director More Insider Trading Tools from MarketBeat Related Companies Acurx Pharmaceuticals Insider Selling Marinus Pharmaceuticals Insider Selling TherapeuticsMD Insider Selling HCW Biologics Insider Selling AIM ImmunoTech Insider Selling Aspira Women's Health Insider Selling Imunon Insider Selling Relmada Therapeutics Insider Selling Talphera Insider Selling Kazia Therapeutics Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:PTIX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
